Neutralizing monoclonal antibodies to respiratory syncytial virus

Abstract

The present invention relates to the identification and cloning of a novel neutralizing human monoclonal antibody to the Respiratory Syncytial Virus. The invention provides such antibodies, fragments of such antibodies retaining RSV-binding ability, chimeric antibodies retaining RSV-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Finally, the invention provides for diagnostic and therapeutic methods employing the antibodies and nucleic acids of the invention.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional application of U.S. application Ser. No. 10 / 425,855, filed Apr. 30, 2003, granted on Jan. 24, 2008, which is a continuation application (and claims the benefit of priority under 35 U.S.C. § 120) of U.S. application Ser. No. 09 / 043,530, filed Oct. 29, 1998. now abandoned, which is a national stage application (under 35 U.S.C. § 371) of and claims priority to PCT Application No. PCT / US96 / 14937, Sep. 18, 1996, which claims priority from U.S. provisional application Ser. No. 60 / 003,9312, Sep. 18, 1995. The disclosures of the prior applications are considered part of (and are incorporated by reference in) the disclosure of this application.FIELD OF THE INVENTION[0002]This invention relates generally to the field of immunology and specifically to monoclonal antibodies which bind to and neutralize respiratory syncytial virus (RSV).BACKGROUND OF THE INVENTION[0003]RSV represents a major health problem, worldwide. ...

AI Technical Summary

Benefits of technology

[0012]A major advantage of the monoclonal antibodies of the invention derives from the fact that they include human CDR3 sequences and, in some embodiments, may be entirely human monoclonal antibodies. Hence in vivo use of the fully human monoclonal antibodies of the invention for immunoprophylaxis and immunotherapy of RSV disease greatly reduces the problem of host immune response to passively administered antibodies. This problem is commonly encountered when the prior art monoclonal antibodies of xenogeneic or chimeric derivation are utilized. A second important aspect of this advantage is the potential safety of these human monoclonal antibodies for gene therapy applications, in which expression of xenogeneic or chimeric proteins containing non-human sequences cannot be terminated.

[0013]The antibodies of the invention are particularly efficacious for immunotherapy of RSV disease when administered directly to the lungs in the form of Fab fragments. Topical delivery of RSV antibodies directly into the lungs has a major advantage over parenteral administration of antibodies for therapy of RSV disease. Polyclonal antibodies delivered by the former route are approximately 80 to 160 times more effective in therapy, thereby decreasing the amount of antibody required for therapy by a factor of 80 to 160. A further reduction in the amount of antibody required for therapy, by a factor of 25 to 50, can be achieved by using monoclonal rather than polyclonal antibodies. This means that the total amount of antibody required for therapy by parenteral treatment can be reduced by a factor of 2000 to 8000 when monoclonal antibodies are administered directly into the lungs for treatment of RSV infection. The ability to utilize Fab or Fd fragments in vivo for respiratory viral infections provides significant advantages over the use of whole antibody molecules including: (1) greater tissue penetration; (2) avoidance of effector functions associated with Fc such as inflammation; and (3) rapid clearance.

Problems solved by technology

This problem is commonly encountered when the prior art monoclonal antibodies of xenogeneic or chimeric derivation are utilized.